Cargando…

Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease

We present an overview of clinical trials involving gene editing using clustered interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9), transcription activator-like effector nucleases (TALENs), or zinc finger nucleases (ZFNs) and discuss the underlying mechanisms. In canc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ernst, Martijn P.T., Broeders, Mike, Herrero-Hernandez, Pablo, Oussoren, Esmee, van der Ploeg, Ans T., Pijnappel, W.W.M. Pim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393410/ https://www.ncbi.nlm.nih.gov/pubmed/32775490 http://dx.doi.org/10.1016/j.omtm.2020.06.022

Ejemplares similares

Sharpening the Molecular Scissors: Advances in Gene-Editing Technology
por: Broeders, Mike, et al.
Publicado: (2019)

A Generic Assay to Detect Aberrant ARSB Splicing and mRNA Degradation for the Molecular Diagnosis of MPS VI
por: Broeders, Mike, et al.
Publicado: (2020)

From Cryptic Toward Canonical Pre-mRNA Splicing in Pompe Disease: a Pipeline for the Development of Antisense Oligonucleotides
por: Bergsma, Atze J, et al.
Publicado: (2016)

Large-Scale Expansion of Human iPSC-Derived Skeletal Muscle Cells for Disease Modeling and Cell-Based Therapeutic Strategies
por: van der Wal, Erik, et al.
Publicado: (2018)

Antisense Oligonucleotides Promote Exon Inclusion and Correct the Common c.-32-13T>G GAA Splicing Variant in Pompe Disease
por: van der Wal, Erik, et al.
Publicado: (2017)

Extension of the Pompe mutation database by linking disease‐associated variants to clinical severity
por: Niño, Monica Y., et al.
Publicado: (2019)

Lack of robust satellite cell activation and muscle regeneration during the progression of Pompe disease
por: Schaaf, Gerben J., et al.
Publicado: (2015)

IGF2-tagging of GAA promotes full correction of murine Pompe disease at a clinically relevant dosage of lentiviral gene therapy
por: Liang, Qiushi, et al.
Publicado: (2022)

GAA Deficiency in Pompe Disease Is Alleviated by Exon Inclusion in iPSC-Derived Skeletal Muscle Cells
por: van der Wal, Erik, et al.
Publicado: (2017)

Lentiviral gene therapy prevents anti-human acid α-glucosidase antibody formation in murine Pompe disease
por: Liang, Qiushi, et al.
Publicado: (2022)

Opportunities and challenges for antisense oligonucleotide therapies
por: Kuijper, Elsa C., et al.
Publicado: (2020)

An in vitro assay to quantify satellite cell activation using isolated mouse myofibers
por: Canibano-Fraile, Rodrigo, et al.
Publicado: (2021)

Satellite cells maintain regenerative capacity but fail to repair disease-associated muscle damage in mice with Pompe disease
por: Schaaf, Gerben J., et al.
Publicado: (2018)

Enzymatic diagnosis of Pompe disease: lessons from 28 years of experience
por: Niño, Monica Y., et al.
Publicado: (2020)

Tagged IDS causes efficient and engraftment-independent prevention of brain pathology during lentiviral gene therapy for Mucopolysaccharidosis type II
por: Catalano, Fabio, et al.
Publicado: (2023)

A generic assay for the identification of splicing variants that induce nonsense-mediated decay in Pompe disease
por: Bergsma, Atze J., et al.
Publicado: (2020)

Quantitative mass spectrometry of TATA binding protein-containing complexes and subunit phosphorylations during the cell cycle
por: Pijnappel, WWM Pim, et al.
Publicado: (2009)

Update of the Pompe variant database for the prediction of clinical phenotypes: Novel disease‐associated variants, common sequence variants, and results from newborn screening
por: de Faria, Douglas O. S., et al.
Publicado: (2020)

Modeling cartilage pathology in mucopolysaccharidosis VI using iPSCs reveals early dysregulation of chondrogenic and metabolic gene expression
por: Broeders, M., et al.
Publicado: (2022)

A genetic modifier of symptom onset in Pompe disease
por: Bergsma, Atze J., et al.
Publicado: (2019)

Novel GAA Variants and Mosaicism in Pompe Disease Identified by Extended Analyses of Patients with an Incomplete DNA Diagnosis
por: in ’t Groen, Stijn L.M., et al.
Publicado: (2020)

Mucopolysaccharidosis: Cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI
por: Brands, Marion M. M. G., et al.
Publicado: (2012)

Perturbation of the yeast N-acetyltransferase NatB induces elevation of protein phosphorylation levels
por: Helbig, Andreas O, et al.
Publicado: (2010)

Broad variation in phenotypes for common GAA genotypes in Pompe disease
por: Niño, Monica Y., et al.
Publicado: (2021)

Orofacial abnormalities in mucopolysaccharidosis and mucolipidosis type II and III: A systematic review
por: de Bode, Chiel J., et al.
Publicado: (2022)

Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long‐term clinical outcome of classic infantile Pompe patients
por: Poelman, Esther, et al.
Publicado: (2020)

Effects of exercise training in 23 adults with Pompe disease receiving enzyme therapy
por: van den Berg, Linda, et al.
Publicado: (2013)

Enteric Viruses in Ready-to-Eat Packaged Leafy Greens
por: Mattison, Kirsten, et al.
Publicado: (2010)

Using Out-of-Batch Reference Populations to Improve Untargeted Metabolomics for Screening Inborn Errors of Metabolism
por: Bongaerts, Michiel, et al.
Publicado: (2020)

Highly contractile 3D tissue engineered skeletal muscles from human iPSCs reveal similarities with primary myoblast-derived tissues
por: van der Wal, Erik, et al.
Publicado: (2023)

Antibodies against recombinant human alpha-glucosidase do not seem to affect clinical outcome in childhood onset Pompe disease
por: van Kooten, Harmke A., et al.
Publicado: (2022)

A Multiplex Assay for the Diagnosis of Mucopolysaccharidoses and Mucolipidoses
por: Langereis, Eveline J., et al.
Publicado: (2015)

Newborn screening for Pompe disease in Italy: Long-term results and future challenges
por: Gragnaniello, Vincenza, et al.
Publicado: (2022)

CHORUS ready to enter second phase of hunt for neutrino oscillation
Publicado: (1998)

The ACE I/D polymorphism does not explain heterogeneity of natural course and response to enzyme replacement therapy in Pompe disease
por: Kuperus, Esther, et al.
Publicado: (2018)

MicroRNAs in Coronary Heart Disease: Ready to Enter the Clinical Arena?
por: Cavarretta, Elena, et al.
Publicado: (2016)

Mucolipidosis type III, a series of adult patients
por: Oussoren, Esmee, et al.
Publicado: (2018)

Epigenetic Characterization of the FMR1 Promoter in Induced Pluripotent Stem Cells from Human Fibroblasts Carrying an Unmethylated Full Mutation
por: de Esch, Celine E.F., et al.
Publicado: (2014)

Gene editing therapy ready for cardiovascular diseases: opportunities, challenges, and perspectives
por: Zhou, Jun, et al.
Publicado: (2021)

Lysosomal glycogen accumulation in Pompe disease results in disturbed cytoplasmic glycogen metabolism
por: Canibano‐Fraile, Rodrigo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_15jfi7o33gv3fpr6oqthr4tdg9